On Monday, January 13, 2020, the PLGG/PLGA (Pediatric Low-Grade Glioma/Astrocytoma) Coalition kicked off their fourth meeting in six years to discuss the latest scientific studies and best practices in clinical trials for treating PLGA patients. The coalition’s goal is to accelerate the pace of PLGA research by finding common ground for evaluating and treating PLGA patients, as well as identifying the scientific direction to better understand low-grade tumors and target them for eradication. This conference has been a catalyst for the most prolific period of PLGA research to date.
Over two days in Ladenburg, Germany, the group discussed a range of important topics including Classifying PLGG within the World Health Organization Coding System, Non-BRAF Tumor Biology, Creating a PLGG Model System, Oncogene Induced Senescence and Micro-Environment, Clinical Trial Updates, the Next Generation of Clinical Trials, and more.
36 leading researchers and clinicians convened from seven countries and 19 research institutions including The Dana-Farber Cancer Institute, University College of Queens (UK), Children’s National Medical Center, Cincinnati Children’s Hospital, Sick Kids (Toronto), Research Institute of McGill Medical, and Washington University of Saint Louis Medical Center. Their collaborative efforts are shaping the future for treating PLGA patients and giving hope to them and their families.
Learn more about the PLGA Fund at PBTF here.
The Pediatric Brain Tumor Foundation today announced the appointment of Ursula Burns and Jordan Wertlieb as inaugural members of the organization’s new Advisory Board. Burns and Wertlieb offer their exceptional business acumen and experience to PBTF, the largest patient advocacy funder of pediatric brain tumor research.
